Contact us at (800) USC-CARE (800-872-2273)

Clinical Trials & Research

Clinical Trials & Research2015-11-20T10:20:49+00:00

Current Studies

Bayer/ Ciprofloxacin Study
The intent of this study is to evaluate the use of ciprofloxacin in an inhaled, powder form, making it more easily accessible to the lungs.

There are 4 weeks of active treatment with study visits once a week, and one brief visit conducted by phone. If necessary, there can be a 30 day washout period, (prior to active study drug) for subjects who are taking exclusionary medications. After the active drug period, there are 2 follow-up visits. There are 8 In-Clinic visits total.

You will be randomly assigned to receive either cipro as 50 or 75 mg or matching placebo taken twice daily. Three in four patients will be assigned to active study drug.

There is no charge to participate in the study, and you will be compensated for your participation.

Tiger 2/ Denufosol Tetrasodium Study
The objective of this study is to evaluate the use of denufosol in a nebulized form to aid in the clearing of mucus from the lungs.

There are 48 weeks (about one year) of active treatment which include 9 clinic visits and 7 brief telephone contacts. There is one follow-up visit. There are 10 In-Clinic visits total.

You will be randomly assigned to either Denufosol or placebo, administered three times daily. You will have a 50% chance of receiving study drug.

There is no charge to participate in the study, and you will be compensated for your participation.

Research

Effect of pioglitazone on sputum biomarkers of lung inflammation and remodeling in patients with cystic fibrosis.

Investigators: Paul Beringer, Pharm.D., Heather Owens, Pharm.D., Ayana Boyd-King, M.D., Adupa Rao, M.D., Helen Baron, M.D., Kamyar Afshar, M.D., Debbie Benitez, RN, MSN.

Purpose: To determine the short-term effects of pioglitazone on biomarkers of airway inflammation and remodeling in patients with cystic fibrosis. The pharmacokinetics and pharmacodynamics will also be assessed.

Duration: The study will take place within the Clinical Trials Unit (CTU) at USC Academic Medical Center and will last for 84 days.

Number of participants: 24

Eligibility: Patients with CF who are greater than 18 years of age, have P. aeruginosa in the sputum, and have an FEV1 greater than 40% of predicted.

Sponsor: Webb Cystic Fibrosis Research Award

Effect of doxycycline on sputum biomarkers of lung inflammation and remodeling in patients with cystic fibrosis.

Investigators: Paul Beringer, Pharm.D., Heather Owens, Pharm.D., Ayana Boyd-King, M.D., Adupa Rao, M.D., Kamyar Afshar, M.D., Debbie Benitez, RN, MSN.

Purpose: To determine the short-term effects of doxycycline on biomarkers of airway inflammation and remodeling in patients with cystic fibrosis. The pharmacokinetics and pharmacodynamics will also be assessed.

Duration: 24

Eligibility: Patients with CF who are greater than 18 years of age, have P. aeruginosa in the sputum, and have an FEV1 greater than 40% of predicted.

Sponsor: Webb Cystic Fibrosis Research Award

More Information

For more clinical trials and research programs, visit the Cystic Fibrosis Foundation website.

Umbrella_KeckMedicine
umbrella-logo
Keck Medicine of USC is the University of Southern California’s medical enterprise, one of only two university-owned academic medical centers in the Los Angeles area.